Optimal three-stage designs for phase II cancer clinical trials

Statistics in Medicine

Volumn 16, Issue 23, 1997, Pages 2701-2711

  Timothy Chen, T ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; METHODOLOGY; PHASE 2 CLINICAL TRIAL; SAMPLE; STATISTICAL ANALYSIS;

CLINICAL TRIALS, PHASE II; DECISION SUPPORT TECHNIQUES; HUMANS; NEOPLASMS; REMISSION INDUCTION; RESEARCH DESIGN; SAMPLE SIZE;

EID: 1842294029     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0258(19971215)16:23<2701::AID-SIM704>3.0.CO;2-1     Document Type: Article

References (17)

1. Buyse, M. and Piedbois, P. 'On the relationship between response to treatment and survival time', Statistics in Medicine, 15, 2797-2812 (1996).
2. Simon, R. 'How large should a phase II trial be?', Cancer Treatment Report, 71, 1079-1085 (1987)
3. Simon, R. 'Optimal two-stage designs for phase II clinical trials', Controlled Clinical Trials, 10, 1-10 (1989).
4. Gehan, E. A. 'The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent', Journal of Chronic Diseases, 13, 346-353 (1961).
5. Fleming, T. R. 'One sample multiple testing procedure for phase II clinical trials', Biometrics, 38, 143-151 (1982).
6. Schultz, J. R., Nichol, F. R., Elfring, G. L. and Weed, S. D. 'Multiple-stage procedures for drug screening', Biometrics, 29, 239-300 (1973).
7. Atkinson, E. N. and Brown, B. W. 'Confidence limits for probability of response in multistage phase II clinical trails', Biometrics, 41, 741-744 (1985).
8. Pocock, S. J. 'Group sequential methods in the design and analysis of clinical trials', Biometrika, 64, 191-199 (1977).
9. O'Brien, P. C. and Fleming, T. R. 'A multiple testing procedure for clinical trials', Biometrics, 35, 549-556 (1979).
10. Green, S. J. and Dahlberg, S. 'Planned versus attained designs in phase II clinical trials', Statistics in Medicine, 11, 853-862 (1992).
11. Ensign, L. G., Gehan, E. A., Kamen, D. S. and Thall, P. F. 'An optimal three-stage design for phase II clinical trials', Statistics in Medicine, 13, 1727-1736 (1994).
12. Thall, P. F. and Simon, R. 'Practical Bayesian guidelines for phase lib clinical trials', Biometrics, 50, 337-349 (1994).
13. Herson, J. 'Predictive probability early termination plans for phase II clinical trials', Biometrics, 35, 775-783 (1979).
14. Sylvester, R. J. 'A Bayesian approach to the design of phase II clinical trials', Biometrics, 44, 823-836 (1988).
15. Brunier, H. C. and Whitehead, J. 'Sample sizes for phase II clinical trials derived from Bayesian decision theory', Statistics in Medicine, 13, 2493-2502 (1994).
16. Thall, P. F. and Simon, R. 'Incorporating historical control data in planning phase II clinical trials, Statistics in Medicine, 9, 215-228 (1990).
17. Mariani, L. and Marubini, E. 'Design and analysis of phase II cancer trials: a review of statistical methods and guidelines for medical researchers', International Statistical Review, 64, 61-88 (1996).